ATE79409T1 - Herstellungsverfahren fuer humanes atriales natriuretisches polypeptid. - Google Patents

Herstellungsverfahren fuer humanes atriales natriuretisches polypeptid.

Info

Publication number
ATE79409T1
ATE79409T1 AT86304723T AT86304723T ATE79409T1 AT E79409 T1 ATE79409 T1 AT E79409T1 AT 86304723 T AT86304723 T AT 86304723T AT 86304723 T AT86304723 T AT 86304723T AT E79409 T1 ATE79409 T1 AT E79409T1
Authority
AT
Austria
Prior art keywords
hanp
fused
protective peptide
atrial natriuretic
peptide
Prior art date
Application number
AT86304723T
Other languages
English (en)
Inventor
Ikuo Ueda
Mineo Niwa
Yoshimasa Saito
Hisashi Yamada
Yoshinori Ishii
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26289399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE79409(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB858515686A external-priority patent/GB8515686D0/en
Priority claimed from GB868600754A external-priority patent/GB8600754D0/en
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Application granted granted Critical
Publication of ATE79409T1 publication Critical patent/ATE79409T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT86304723T 1985-06-20 1986-06-19 Herstellungsverfahren fuer humanes atriales natriuretisches polypeptid. ATE79409T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB858515686A GB8515686D0 (en) 1985-06-20 1985-06-20 Production of-human atrial natriuretic polypeptide
GB868600754A GB8600754D0 (en) 1986-01-14 1986-01-14 Human atrial natriuretic polypeptide
EP86304723A EP0206769B2 (de) 1985-06-20 1986-06-19 Herstellungsverfahren für humanes atriales natriuretisches Polypeptid

Publications (1)

Publication Number Publication Date
ATE79409T1 true ATE79409T1 (de) 1992-08-15

Family

ID=26289399

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86304723T ATE79409T1 (de) 1985-06-20 1986-06-19 Herstellungsverfahren fuer humanes atriales natriuretisches polypeptid.

Country Status (5)

Country Link
US (2) US6403336B1 (de)
EP (2) EP0206769B2 (de)
JP (1) JPH0633316B2 (de)
AT (1) ATE79409T1 (de)
DE (1) DE3686365T3 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3686365T3 (de) 1985-06-20 2000-07-27 Fujisawa Pharmaceutical Co., Ltd. Herstellungsverfahren für humanes atriales natriuretisches Polypeptid.
US5340725A (en) * 1986-10-09 1994-08-23 Fujisawa Pharmaceutical Co., Ltd. Expression vector for insulin-like growth factor I and method of production
EP0264074B1 (de) * 1986-10-09 1992-12-30 Fujisawa Pharmaceutical Co., Ltd. Expressionsvektor für menschlichen insulinähnlichen Wachstumsfaktor-I
US4987070A (en) * 1987-03-04 1991-01-22 Suntory Limited Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins
US7049102B1 (en) 1989-09-22 2006-05-23 Board Of Trustees Of Leland Stanford University Multi-gene expression profile
AUPN283195A0 (en) * 1995-05-05 1995-06-01 Australian Water Technologies Pty Ltd Method for the detection of viable cryptosporidium parvum cells
DE19535445A1 (de) * 1995-09-23 1997-03-27 Boehringer Mannheim Gmbh Verfahren zur Herstellung von natriuretischen Peptiden über Streptavidin-Fusionsproteine
ES2328223T3 (es) * 2000-05-10 2009-11-11 Asubio Pharma Co., Ltd. Metodos para reducir la formacion de subproductos en la produccion de polipeptidos geneticamente modificados.
US7357124B2 (en) * 2002-05-10 2008-04-15 Philip Morris Usa Inc. Multiple capillary fuel injector for an internal combustion engine
US7459290B1 (en) 2004-03-30 2008-12-02 Iowa State University Research Foundation, Inc. Methods of using functional 30S subunits
US7337768B2 (en) * 2004-05-07 2008-03-04 Philip Morris Usa Inc. Multiple capillary fuel injector for an internal combustion engine
WO2007047504A2 (en) * 2005-10-14 2007-04-26 Biorexis Pharmaceutical Corporation Natriuretic peptide modified transferrin fusion proteins

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54163600A (en) * 1977-11-08 1979-12-26 Genentech Inc Microbiological polypeptide expression method and means
GB2008123B (en) * 1977-11-08 1982-09-08 Genentech Inc Method of means for microbial polypeptide expression
DK339781A (da) * 1980-08-05 1982-02-06 Searle & Co Syntetisk gen
EP0116784B1 (de) * 1982-02-22 1992-06-10 Queen's University At Kingston Atrial natriuretischer Faktor
GB8314362D0 (en) 1983-05-24 1983-06-29 Celltech Ltd Polypeptide and protein products
US4617149A (en) * 1983-09-21 1986-10-14 Eli Lilly And Company Growth hormone release factor analogs
US4703004A (en) * 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4952561A (en) * 1984-02-07 1990-08-28 Merck & Co., Inc. Cardiac atrial peptides
DK108685A (da) * 1984-03-19 1985-09-20 Fujisawa Pharmaceutical Co Vaekstfaktor i
US4745179A (en) * 1984-04-02 1988-05-17 Fujisawa Pharmaceutical Co., Ltd. 59 Valine insulin-like growth factor I and process for production thereof
US4851349A (en) * 1984-04-12 1989-07-25 Mitsubishi Chemical Industries Limited Expression vectors encoding cardionatrin and cardiodilatin
DE3588006T2 (de) * 1984-04-19 1995-08-10 Scios Nova Inc Atrielle natriumuretische/gefässerweiterende polypeptide.
AU600652B2 (en) 1984-06-08 1990-08-23 Hisayuki Matsuo Human atrial natriuretic peptide and gene encoding same
CA1340625C (en) * 1984-06-29 1999-07-06 Peter L. Davies Cloned cardionatrin cdna
AU5668486A (en) * 1985-03-29 1986-10-23 Biotechnica International Inc. Secretion vector
EP0222876A1 (de) * 1985-05-07 1987-05-27 California Biotechnology, Inc. Fusionsproteine für enzymimmunotestverfahren
DE3686365T3 (de) 1985-06-20 2000-07-27 Fujisawa Pharmaceutical Co., Ltd. Herstellungsverfahren für humanes atriales natriuretisches Polypeptid.
EP0207044A1 (de) * 1985-06-20 1986-12-30 Monsanto Company Freisetzung von Peptiden aus Polypeptiden
ZA864555B (en) * 1985-06-20 1987-11-25 Monsanto Co Release of peptides from polypeptides
GB8518753D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Microbiological products
US4987070A (en) * 1987-03-04 1991-01-22 Suntory Limited Use of a 97 amino acid leader sequence from the E. coli B-galactosidase gene for the production of hanp and hptc as fusion proteins

Also Published As

Publication number Publication date
EP0206769B2 (de) 1999-11-10
US20030170811A1 (en) 2003-09-11
DE3686365T3 (de) 2000-07-27
JPH0633316B2 (ja) 1994-05-02
EP0206769B1 (de) 1992-08-12
US6403336B1 (en) 2002-06-11
EP0206769A3 (en) 1988-12-28
EP0206769A2 (de) 1986-12-30
JPH067187A (ja) 1994-01-18
EP0440311A1 (de) 1991-08-07
DE3686365D1 (de) 1992-09-17
DE3686365T2 (de) 1993-01-14

Similar Documents

Publication Publication Date Title
EP0150126A3 (en) The synthesis of protein with an identification peptide
EP0238023A3 (en) Process for the production of protein products in aspergillus oryzae and a promoter for use in aspergillus
NO174351C (no) Fremgangsmåte for fremstilling av human insulinforlöper samt DNA-sekvens og vektor til anvendelse av fremgangsmåten
CZ738982A3 (en) Human immune interferon and derivative thereof, separated dna with sequence encoding human immune interferon, recombinant cloning vector, replicable expression vector, recombinant micro-organism or cellular culture, pharmaceutical preparation, process for preparing the human immune interferon and its use
IE883612L (en) Vectors and compounds for direct expression of activated human protein c
ATE79409T1 (de) Herstellungsverfahren fuer humanes atriales natriuretisches polypeptid.
EP0722461A4 (de) Expression eines fusionspolypeptides, das ohne leadersequenz aus dem cytoplasma transportiert wird
EP0824148A3 (de) Polyester-Synthase Gen und Verfahren zur Herstellung von Polyestern
DE69929805D1 (de) Modifiziertes e.coli enterotoxin ii signalpeptid sowie ein mikroorganismus der ein fusionsprotein sowie ein heterologes protein exprimiert
DK0531404T3 (da) Ubiquitin-specifik protease
EP0211299A3 (en) Fusion proteins, method for their production and their use
AU1003888A (en) Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host, process, expression vector and recombinant host therefore and pharmaceutical use thereof
WO1996017941A3 (en) Production of c-terminal amidated peptides from recombinant protein constructs
CA2198968A1 (en) Process for production of secretory kex2 derivatives
IE871871L (en) Cloning and expression of acidic fibroblast growth factor
DE3479734D1 (en) Novel, physiologically active polypeptides and production method thereof
EP0195680A3 (de) Proteinsynthese mit einem Identifizierungspeptid
AU572171B2 (en) Polypeptides
CA2011378A1 (en) Achromobacter protease i gene and gene product thereof
KR940007182A (ko) 재조합 인간 알파 인터페론 발현벡터, 균주 및 이를 이용한 인간 알파 인터페론의 제조방법
EP0750040A3 (de) Varianten des Makrophagen-stimulierendes-Proteins und Verfahren zur ihrer Herstellung
RU92004585A (ru) Промотор, днк-последовательность, вектор, клетки, способ экспрессии днк
RU93032287A (ru) Способ получения окситоцина и рекомбинантные плазмидные днк ptoteilox и штаммы escherichia coli tg1/ptoteilox для его осуществления
EP1517913A4 (de) Eine mycobacterium tuberculosis kodierende sequenz zur expression von heterologen proteinen
GB1210557A (en) Synthesis of polypeptides containing cysteine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee